Poly(ADP-ribose) polymerase inhibition with HYDAMTIQ reduces allergen-induced asthma-like reaction, bronchial hyper-reactivity and airway remodelling

Authors

  • Laura Lucarini,

    1. Department of NEUROFARBA, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy
    Search for more papers by this author
    • These authors contributed equally to this work.
  • Alessandro Pini,

    1. Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence, Florence, Italy
    Search for more papers by this author
    • These authors contributed equally to this work.
  • Elisabetta Gerace,

    1. Department of NEUROFARBA, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy
    Search for more papers by this author
  • Roberto Pellicciari,

    1. Department of Chemistry and Drug Technology, University of Perugia, Perugia, Italy
    Search for more papers by this author
  • Emanuela Masini,

    Corresponding author
    1. Department of NEUROFARBA, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy
    • Correspondence to: Prof. Emanuela MASINI, M.D.,

      Department of NEUROFARBA, Section of Pharmacology and Toxicology,

      University of Florence, Viale G. Pieraccini no. 6, Firenze 50139, Italy.

      Tel.: +39 055 4271 233

      Fax: +39 055 4271 280

      E-mail: emanuela.masini@unifi.it

    Search for more papers by this author
  • Flavio Moroni

    1. Department of NEUROFARBA, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy
    Search for more papers by this author

Abstract

Activation of poly(ADP-ribose) polymerases (PARPs) is considered a key event in the molecular and cellular processes leading from acute asthma attacks to bronchial hyper-reactivity, leucocyte recruitment, chronic inflammation, airway remodelling and lung damage. The present investigation has been carried out to investigate the action of hydroxyl-dimethylaminomethyl-thieno[2,3-c]isoquinolin-5(4H)-one (HYDAMTIQ), a new potent PARP inhibitor, in the process leading from asthma-like events to airway damage. Ovalbumin-sensitized guinea pigs exposed two times to allergen inhalation were treated for 8 days with vehicle or HYDAMTIQ. Asthma-like signs, bronchial hyper-reactivity to methacholine, cytokine production, histamine release from mast cells, airway remodelling, collagen deposition and lung damage were evaluated. Repeated HYDAMTIQ administration (1-10 mg/kg/day i.p.) reduced lung PARP activity, delayed the appearance and reduced the severity of allergen-induced cough and dyspnoea and dampened the increased bronchial responses to methacholine. HYDAMTIQ-treated animals presented reduced bronchial or alveolar abnormalities, lower number of eosinophils and other leucocytes in the lung and decreased smooth muscle or goblet cell hyperplasia. The treatment also reduced lung oxidative stress markers, such as malondialdehyde or 8-hydroxy-2′-deoxyguanosine and the lung content of pro-inflammatory cytokines (TNF-α, interleukin (IL)-1β, IL-5, IL-6 and IL-18). Finally, mast cells isolated from the peritoneal or pleural cavities of sensitized, HYDAMTIQ-treated animals had a reduced ability to release histamine when exposed to ovalbumin in vitro. Our findings support the proposal that PARP inhibitors could have a therapeutic potential to reduce chronic lung inflammation, airway damage and remodelling in severe unresponsive asthmatic patients.

Ancillary